Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients

Androgen deprivation therapy (ADT) is first‐line palliative treatment in androgen receptor‐positive (AR+) salivary duct carcinoma (SDC), and response rates are 17.6–50.0%. We investigated potential primary ADT resistance mechanisms for their predictive value of clinical benefit from ADT in a cohort...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: van Boxtel, Wim, Verhaegh, Gerald W., van Engen‐van Grunsven, Ilse A., van Strijp, Dianne, Kroeze, Leonie I., Ligtenberg, Marjolein J., van Zon, Hans B., Hendriksen, Yara, Keizer, Diederick, van de Stolpe, Anja, Schalken, Jack A., van Herpen, Carla M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Tumor Markers and Signatures
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187215/
https://ncbi.nlm.nih.gov/pubmed/31745978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32795
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados